Modular Medical, Inc. filings document a Nevada medical device issuer developing insulin delivery technology, including registration statements, material-event reports, shareholder approvals, and capital-structure changes. Disclosures cover common stock, warrants and pre-funded warrants, amendments to authorized shares, and the completed one-for-thirty reverse stock split.
MODD filings also record material agreements and financing arrangements, Nasdaq continued-listing matters, operating expense reductions, governance actions, risk-related disclosures, and securities registration information for the company’s Pivot-focused insulin pump business.
Modular Medical, Inc. (MODD) reported that director Duane DeSisto resigned from its board effective October 26, 2026, after being elected at the fiscal 2027 annual meeting held October 23. The company stated that his resignation was not due to a disagreement concerning its operations, policies or practices.
Shareholders elected all six director candidates—James E. Besser, Paul DiPerna, Duane DeSisto, Steven Felsher, Philip Sheibley and Ellen O’Connor Vos—to serve until the next annual meeting and until a successor is elected and qualified, or earlier resignation or removal. A quorum represented approximately 65% of outstanding common shares entitled to vote. Two reported proposals were approved; one received 2,294,200 votes for and another received 6,171,976 votes for.
Modular Medical, Inc. director Steven G. Felsher acquired 25 common shares under the company’s Outside Director Compensation Plan on September 30, 2026; his reported direct common-share position afterward was 8,538 shares, reflecting the 1-for-30 reverse stock split effected March 31, 2026. He also received an option for 250 shares, fully vested and exercisable on the grant date at a $1.95 exercise price and expiring September 30, 2036; the reported post-grant total for that derivative-security class was 250 options.
Modular Medical, Inc. (MODD) issued director Duane M. DeSisto 83 shares of common stock on September 30, 2026, under its Outside Director Compensation Plan. His direct holdings following the award were 9,412 shares. The reported share amount reflects the impact of a 1-for-30 reverse stock split effected March 31, 2026.
Modular Medical, Inc. director Carmen B. Volkart received an award of 108 common shares on September 30, 2026, under the Outside Director Compensation Plan. Her directly held position after the award was 1,036 shares; this post-transaction amount reflects the impact of the 1-for-30 reverse stock split effected March 31, 2026.
Modular Medical, Inc. granted director Jeff D. Goldberg 250 options to purchase common stock on September 30, 2026, covering 250 common shares. The options were fully vested and exercisable on the grant date, have a $1.95 exercise price, and expire September 30, 2036. The reported post-transaction position was 250 options in that derivative-security class.
Modular Medical, Inc. (MODD) director Ellen O'Connor Vos received a grant of 250 options to purchase common stock on September 30, 2026. The options were fully vested and exercisable on the grant date, at an exercise price of $1.95 per share. The reported post-grant position in this option class was 250 options.
Modular Medical, Inc. director Philip Brent Sheibley received a grant of an option to purchase 250 shares of common stock on September 30, 2026. The option was fully vested and exercisable on the grant date, has an exercise price of $1.95 per share, and expires September 30, 2036.
Modular Medical, Inc. director and 10% owner Morgan C. Frank received two grants of options to purchase common stock on September 30, 2026: 62 options and 250 options, each with an exercise price of $1.95. The options were granted under the company's Outside Director Compensation Plan.
Modular Medical, Inc. (MODD) is asking shareholders at its October 23, 2026 annual meeting to elect six directors, approve an amendment adding 2,500,000 shares to the 2017 Equity Incentive Plan, and ratify Farber Hass Hurley LLP as auditor for fiscal 2027. The nominees are James E. Besser, Paul DiPerna, Duane DeSisto, Steven Felsher, Philip Sheibley and Ellen O’Connor Vos; Jeffrey Goldberg and Carmen Volkart are not standing for re-election. Common shares outstanding and entitled to vote totaled 9,495,823 as of September 10, 2026. The board expects to appoint a lead independent director after the meeting.
The plan currently authorizes 455,557 shares; as of the record date, 422,119 shares were subject to existing awards and 21,120 were available for future awards. Modular Medical disclosed substantial doubt about its ability to continue as a going concern within one year from issuance of the financial statements in its Form 10-Q for the quarter ended June 30, 2026, citing operating losses and negative cash flows. It expects further debt or equity financing and significant dilution to commercialize its initial pump product. Fiscal 2026 net loss was $28,241,433, compared with $18,824,126 in fiscal 2025.